U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Wednesday.The Dow traded down 0.35% to 46,129.26 while the NASDAQ fell 0.47% to 22,468.39. The S&P 500 also fell, dropping, 0.40% to 6,630.54.Check This Out: Top 2 Tech Stocks That May Plunge This MonthLeading and Lagging SectorsEnergy shares jumped by 1.9% on Wednesday.In trading on Tuesday, materials stocks fell by 1.5%.Top HeadlineCrude oil inventories in the U.S. declined by 0.607 million barrels i ...

He also leads the investing group IPO Edge , which offers actionable information on growth stocks through first-look IPO filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initi ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Sarepta Therapeutics caused the company to misrepresent or fail to disclose that (i) ELEVIDYS posed significant safety risks to patients: (ii) ELEVIDYS trial regimes and pro ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate (“Cytokinetics” or the “Company”) (NASDAQ: CYTK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Cytokinetics a ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the "Class Period†). Jasper investors have until November 18, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN JASPER THERAPEUTICS, INC. (JSPR), CONTACT THE LAW OFFICES OF HOWA. ...

PresentationGood day, and welcome to the top line results for AMT-130 in Huntington's disease. [Operator Instructions] As a reminder, this call may be recorded. I would now like to turn the call over to Chiara Russo, Senior Director, Investor Relations.Chiara Russo Thank you. This morning, uniQure announced pivotal data on patients treated with our investigational gene therapy, AMT-130 in our ongoing Phase I/II clinical trials in Huntington's disease, taking place in the U.S., EU and the U.K. This 3-year u ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

PresentationRegina GraulCEO, President & Director Good morning, everyone. Yesterday, we announced Cyclerion's transformational relaunch as a neuropsychiatric company, supported by an MIT licensing agreement that secures foundational intellectual property. A copy of this release and presentation to accompany this call are available on the Investor Relations section of our website at ir.cyclerion.com. I am Regina Graul, Chief Executive Officer of Cyclerion Therapeutics. Thank you for joining us for the Cycler ...

HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--FUJIFILM Biotechnologies today celebrated the grand opening of its manufacturing site in Holly Springs, North Carolina. The newest addition to FUJIFILM Biotechnologies' global network represents one of the largest commercial-scale cell culture biomanufacturing sites in North America. The first phase of the planned $3.2 billion manufacturing site opens with a capacity of 8 x 20,000 liters (L) mammalian cell culture bioreactors to encompass drug product and d. ...

Accessibility StatementSkip Navigation LAS VEGAS, Sept. 24, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ('Avant' or the 'Company') today announced the retraction of its press release issued on September 24, 2025, regarding a purported Joint Venture and License Agreement with Art-Islets Pte. Ltd. and Austrianova (SGAustria Pte. Ltd.). 440k+Newsrooms &Influencers 9k+Digital MediaOutlets 270k+JournalistsOpted In GET STARTED Also from this source Forward-Looking Statements This communication m ...